Monday, Dec 22nd

Last update08:50:24 PM GMT






You are here: News BioMedTech

Massive demand for top medical device developers

Tom-OakleyCambridge’s reputation as a hotspot for medical device innovation has been ramped up a few extra notches by the progress of young and increasingly powerful consultancy Springboard.

Medical smartwatch targets $2bn market

Aseptika-BuddywotchAseptika in Cambridge UK has accelerated development of its medical wearable Smartwatch, the BuddyWOTCH, which is aimed at a market worth an estimated $2 billion.

Crescendo raises further funding

Mike-Romanos Crescendo BiologicsCrescendo Biologics in Cambridge UK has secured a further equity investment from Astellas Venture Management (AVM) to support the discovery and development of new Humabody antibody fragment therapeutics in oncology.

Genomics powerhouse spins out of Sanger in £12.5m launch

Andy-Sandham-14M GenomicsA new genomics powerhouse, spun out of the world famous Wellcome Trust Sanger Institute, has been launched in the Cambridge UK technology cluster with a £12.5 million financing.

Cambridge move gives Abzena springboard to global growth

Babraham-Research-CampusLife science company Abzena is already reaping the benefits of moving its corporate HQ to the Cambridge UK medical technology cluster.

Procter & Gamble turns to Eagle for bioinformatics software

Abel-Ureta-VidalGlobal consumer products giant Procter & Gamble (P&G) has turned to Cambridge bioinformatics technology to accelerate certain areas of research.

Horizon taps £2.9bn large molecule market

Darrin-Disley-Horizon DiscoveryHorizon Discovery, the Cambridge UK medical technology trailblazer, has lined up a new multi-billion pound market with a significant first deal in the segment.

Clinical trials boost via Linguamatics-Thomson Reuters alliance

Linguamatics John BrimacombeA technology collaboration between Cambridge UK text analytics specialist Linguamatics and the IP and science business of Thomson Reuters in Philadelphia will lead to more effective clinical trials and drug discovery, the partners believe.

Wellcome spin-off wins £1m in genomics revolution

Congenica leadership team, from left includes, Andy Richards, Richard Durbin, CEO Tom Weaver, Nick Lench,  Matthew HurlesCongenica, a Cambridge UK genomics company whose technology will allow definitive diagnosis of children with rare genetic diseases in minutes rather than years, has secured up to £1 million funding from Cambridge Innovation Capital.

China sanctions Sareum patent

Sareum-MitchellThe China Patent & Trademark Office has granted Cambridge-based Sareum a patent for one the medical technology company's key drug discovery inventions.

Consort Medical shares soar on interim revenue growth

Consort Medical CEO Jon Glenn - shares soar on interim revenue growthConsort Medical, the Cambridge-based medical technology group, gained a healthy injection to its UK share price on the back of interim revenue growth.

Horizon CEO wins top life sciences accolade

Horizon Discovery CEO Darrin Disley Horizon Discovery CEO Darrin Disley has scooped one of the top honours in the life science industry after being named Executive of the Year at last night’s SCRIP Awards in London.

Sagentia helps develop wearable smart device to deter smoking

Sagentia HQ at Harston Mill - the team helping smokers quitSagentia, the Cambridge UK technology innovator, is working on what is said to be the world’s first programmable and wearable nicotine delivery device to help people quit smoking.

Cambridge dominates GSK medical discovery challenge

Cambridge University Professor Steve-JacksonA trio of medical initiatives from Cambridge University have been chosen out of hundreds of applications from around the world to be fast-tracked to commercialisation by drugs giant GSK.

Widening losses hit GW shares despite US growth plan

Justin-GoverThe bottom line clearly means more to biotech investors than potential in the portfolio as widening losses sent the shares of Cambridge medical technology business GW Pharmaceuticals sharply south in the UK.

Historic Cambridge alliance to push boundaries of cancer discovery

Menelas Pangalos, executive vic-president, Innovative Medicines and Early Development at AstraZenecaCambridge is to host an historic alliance between scientists at AstraZeneca and investigators at Cancer Research UK designed to push the boundaries of cancer discovery and generate new drugs.

  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  5 
  •  6 
  •  7 
  •  8 
  •  9 
  •  10 
  •  Next 
  •  End 
  • »

Page 1 of 67